National Institute of Genomic Medicine

National Institute of Genomic Medicine

The National Institute of Genomic Medicine is one of Mexico's twelve national institutes under the Secretariat of Health. The institute was founded in 2004, with its official headquarters built eight years later. INMEGEN is dedicated to the development of genomic medicine for the Mexican population. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for National Institute of Genomic Medicine, Mexico, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

69%


Total
Publications

2.2K


Total Open
Publications

1.5K


Total
Citations

81K


Open Access
Percentage

69%


Total
Publications

2.2K


Total Open
Publications

1.5K


Total
Citations

81K

Wikipedia

Website

download

Breakdown

15% 49% 4% 32%

Publisher Open

15%

Both

49%

Other Platform Open

4%

Closed

32%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

020406080100120140160180200220240260Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

64%OA Journal

OA Journal 64%

862

Hybrid 26%

351

No Guarantees 10%

136

Other Platform Open

Domain 89%

994

Other Internet 29%

327

Institution 18%

199

Public 5%

58

Preprint 0%

4

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
1K
DOI
Other Internet
296
Europe PMC
Domain
81
Figshare
Public
55
Unknown Repository
Other Internet
44
DANS - Data Archiving and Networked Services
Institution
35
Elsevier - Scopus
Institution
29
AECID Library - Americanae
Institution
24
Conicet
Institution
21
University of Groningen / Centre for Information Technology - University of Groningen research database
Institution
19
1 / 14

Data updated 18 August 2025

Share

Share

Share